165 related articles for article (PubMed ID: 38087126)
1. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.
Cohen NA; Choi D; Garcia N; Choi NK; Picker E; Krugliak Cleveland N; Cohen RD; Dalal SR; Pekow J; Rubin DT
Dig Dis Sci; 2024 Feb; 69(2):579-587. PubMed ID: 38087126
[TBL] [Abstract][Full Text] [Related]
2. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
Choi D; Stewart AP; Bhat S
Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
[TBL] [Abstract][Full Text] [Related]
3. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
Rowan C; Ungaro R; Mehandru S; Colombel JF
Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
[TBL] [Abstract][Full Text] [Related]
4. Ozanimod: A Review in Ulcerative Colitis.
Paik J
Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
[TBL] [Abstract][Full Text] [Related]
6. Update on ozanimod for ulcerative colitis.
Antonelli EK; Del Sordo R; Morelli O; Villanacci V; Bassotti G
Drugs Today (Barc); 2022 Jul; 58(7):351-367. PubMed ID: 35851870
[TBL] [Abstract][Full Text] [Related]
7. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
Aoun R; Hanauer S
Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M
J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686
[TBL] [Abstract][Full Text] [Related]
9. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
[TBL] [Abstract][Full Text] [Related]
10. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
Sands BE; Schreiber S; Blumenstein I; Chiorean MV; Ungaro RC; Rubin DT
J Crohns Colitis; 2023 Dec; 17(12):2012-2025. PubMed ID: 37436357
[TBL] [Abstract][Full Text] [Related]
11. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
[TBL] [Abstract][Full Text] [Related]
13. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes.
Cohen NA; Weber CR; Cheng JX; Choi D; Garcia NM; Choi NK; Rubin DT
J Crohns Colitis; 2024 Apr; 18(4):638-641. PubMed ID: 37879626
[TBL] [Abstract][Full Text] [Related]
14. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.
Cohen NA; Choi D; Choden T; Cleveland NK; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2407-2409.e2. PubMed ID: 35381385
[TBL] [Abstract][Full Text] [Related]
15. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG
Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720
[TBL] [Abstract][Full Text] [Related]
16. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
Sands B; Pondel M; Silver M; Petersen A; Wolf D; Panaccione R; Loftus E; Colombel JF; Sturm A; D'Haens G
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S8. PubMed ID: 37461950
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R
Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447
[TBL] [Abstract][Full Text] [Related]
18. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954
[TBL] [Abstract][Full Text] [Related]
19. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956
[TBL] [Abstract][Full Text] [Related]
20. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
